RBKS (Ribokinase) inhibitors belong to a class of chemical compounds that primarily target the enzyme ribokinase, an essential player in cellular metabolism. Ribokinase is responsible for phosphorylating ribose, a critical step in the conversion of ribose into ribose-5-phosphate, an important component of the pentose phosphate pathway (PPP). The PPP is a crucial metabolic pathway that provides the cell with ribose for nucleotide synthesis and generates reducing equivalents in the form of NADPH, used in various biosynthetic reactions and oxidative stress defense. By inhibiting ribokinase, RBKS inhibitors disrupt the normal flow of ribose metabolism, leading to profound impacts on cellular physiology.
The mechanism of action of RBKS inhibitors involves binding to the active site of ribokinase, interfering with its ability to catalyze the phosphorylation of ribose. This disruption prevents ribose from entering the PPP, affecting nucleotide production and NADPH generation. Consequently, cells exposed to RBKS inhibitors may experience reduced DNA and RNA synthesis due to limited ribose-5-phosphate availability, which can have downstream effects on cell growth and proliferation. Additionally, the decrease in NADPH levels can compromise the cell's ability to combat oxidative stress, making it more vulnerable to reactive oxygen species. RBKS inhibitors are valuable tools in scientific research for studying cellular metabolism and understanding the role of ribokinase in maintaining cellular homeostasis. Their ability to perturb nucleotide biosynthesis and redox balance provides insights into the fundamental processes governing cell function and survival, offering potential applications in various areas of biological and biochemical research.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits BCR-ABL kinase, studied in the research of CML. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Crosslinks DNA, leading to DNA damage and cell death. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Selective estrogen receptor modulator (SERM) for breast cancer. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Targets multiple kinases in angiogenesis and cell signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Inhibits EGFR kinase in non-small cell lung cancer. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Inhibits dihydrofolate reductase, interfering with DNA synthesis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor used in multiple myeloma therapy. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Stabilizes microtubules, disrupting cell division. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Androgen receptor antagonist for prostate cancer. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Targets mutant BRAF kinase in melanoma. | ||||||